about
Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependenceEfficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.Improving temporal efficiency of outpatient buprenorphine induction.Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trialConsumer attitudes about opioid addiction treatment: a focus group study in New York City.Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.Home- versus office-based buprenorphine inductions for opioid-dependent patients.Antidepressant treatment does not improve buprenorphine retention among opioid-dependent personsBuprenorphine: new treatment of opioid addiction in primary care.A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions.A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphineCommunity-wide measures of wellness in a remote First Nations community experiencing opioid dependence: evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program.E-cigarette knowledge, attitudes, and use in opioid dependent smokersBuprenorphine-naloxone maintenance following release from jail.Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.Comparing buprenorphine induction experience with heroin and prescription opioid users.Maintenance medication for opiate addiction: the foundation of recovery.A urinalysis-based comparative study of treatment adherence on buprenorphine and buprenorphine/naloxone combination used as opioid substitution therapy.Mobile phone messaging for illicit drug and alcohol dependence: A systematic review of the literature.Factors associated with complicated buprenorphine inductionsSupporting mothers' engagement in a community-based methadone treatment programA pilot study of a distress tolerance treatment for opiate-dependent patients initiating buprenorphine: rationale, methodology, and outcomesPredictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.A buprenorphine education and training program for primary care residents: implementation and evaluation.Characteristics of inmates witnessing overdose events in prison: implications for prevention in the correctional settingOutcomes among buprenorphine-naloxone primary care patients after Hurricane Sandy.Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.Psychiatric comorbidity, red flag behaviors, and associated outcomes among office-based buprenorphine patients following Hurricane Sandy.A case series of buprenorphine/naloxone treatment in a primary care practice.Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies.The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.Text message reminders for improving patient appointment adherence in an office-based buprenorphine program: A feasibility study.Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.Buprenorphine shared medical appointments for the treatment of opioid dependence in a homeless clinic.Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.Substance use prevalence and screening instrument comparisons in urban primary care.Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program.NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
P2860
Q26865674-30CEAD61-546F-4AD3-87D2-55566738863EQ30276657-2AFD562E-FDEF-4A83-A390-AFBCB64AC8ACQ30425074-8C5D5ACE-F71D-484E-865B-454E490A3917Q30432435-35E08B3C-736A-40BC-AABB-72BD8E917014Q33576957-2BBADF29-38AB-4D2D-9A76-4020CC25F180Q33688813-E7CAF6EE-AFC8-44F8-AA08-5BE85815108FQ33769847-E085E14F-1513-4C52-9DD9-9196C9B529F0Q34023435-313FCDD6-814A-4616-B34A-5DB592FF5D8FQ34667890-235FCB3E-CCA7-4150-BE8A-1CADCF571610Q34850334-E4DD88FD-795A-4FC4-A2F5-4A498E9D4790Q34980314-7DB71D2A-C2D6-47FF-A90B-D4BA08AC5BBEQ35077108-DB885B14-391B-445B-A18E-327AB0A19582Q35243651-FF771EF0-A6DC-4ED3-9B4B-63CD68EE525BQ35848205-5B472D54-A14B-4DE4-B981-916501B4C0A0Q35924202-0233191D-498D-45AB-ADF6-05E85B63D66AQ35954416-6DCB1592-5D6B-41EF-8F5A-13A59728BA63Q36138164-C204DAF8-7831-48C6-8238-932EB6766458Q36235101-1857E0B7-AEBB-4DEA-9BE8-D45D16F4E8B2Q36363902-63BAA9E4-8B85-4AEA-8003-A3B923C75611Q36585261-03D87F41-4D4D-468C-8DA1-9E89525825AAQ36877159-F253C9E0-961B-462D-8F3C-E1282BD7EC81Q36926561-DD82E1B2-5A51-41F5-A7CE-F03B8FAD7D9EQ36952763-8A9A628A-E847-4E65-8FF1-E19D2D775C17Q36960916-2D6C581F-3FFA-4E27-8054-201343EE345DQ37237877-201B94C3-40AB-4DE7-84B7-5BCCAD39C2FFQ37284016-2961994D-07CA-4B4B-B69B-5E980C395F9CQ37613483-3E7A8A46-55C3-4F7A-8C0E-0096C7B3F69BQ37673456-F4A040F4-F4FD-466E-B8B0-5620C978B399Q37689222-7C1A5D56-33AC-4D65-BFEB-6F53C155E9DCQ37947698-49DB10E7-CB56-4BB1-A152-38E3158979A0Q38244651-E7EB3EF9-D165-4514-92C3-54C257B6347EQ38634946-B63EF19E-7E23-43AC-858E-3DAD9897121CQ38643890-A4D23806-367E-4D4A-8DFB-024B1F80A592Q38695672-6988FC8F-FDD7-43F5-8A50-BAE3C549511BQ39023409-F9FB0175-127C-46D1-833F-205A17719E72Q39135185-CB5B4C9F-C3AE-4FF3-96FF-B6D9C5EBFCF6Q39986609-F71E05CF-DC9F-4DE9-BA60-B6A0DF5CDD9EQ41210999-6004BA64-7ED2-475A-911A-96DE20C97A2AQ41367554-AA82F0AF-301D-4E8D-916E-56B8A31F958EQ42289728-254C86E4-D18C-4548-B770-69C391639C70
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Home buprenorphine/naloxone induction in primary care
@en
Home buprenorphine/naloxone induction in primary care.
@nl
type
label
Home buprenorphine/naloxone induction in primary care
@en
Home buprenorphine/naloxone induction in primary care.
@nl
prefLabel
Home buprenorphine/naloxone induction in primary care
@en
Home buprenorphine/naloxone induction in primary care.
@nl
P2860
P1476
Home buprenorphine/naloxone induction in primary care
@en
P2093
Danae DiRocco
Ellie Grossman
P2860
P2888
P304
P356
10.1007/S11606-008-0866-8
P577
2008-12-17T00:00:00Z